FLSCFrazier Life Sciences Acquisition II (Stock-Only)
2026-incorporated blank check SPAC targeting business combinations in life sciences.
$10IPO price
$75MRaised
$10.29Day-1 close
2.90%Day-1 return
2026-incorporated blank check SPAC targeting business combinations in life sciences.
Company description (source: StockAnalysis)
Frazier Life Sciences Acquisition Corp II focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2026 and is based in Palo Alto, California.
51CFO read: CFO must navigate SPAC accounting (ASC 815), M&A due diligence, and life sciences target valuation.
Management details per the SEC prospectus.
Does your company need this kind of CFO?
51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.
Talk to us